BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Novo Nordisk A/S (NVO) Wins EU Panel's Recommendation for Tresiba


10/19/2012 7:04:10 AM

Novo Nordisk A/S (NOVOB) won the backing of a European Union advisory panel for its new insulin Tresiba, paving the way for increased competition in the $35 billion diabetes market. Tresiba, also known as degludec, was recommended by the European Medicines Agency’s Committee for Medicinal Products for Human Use, the London-based regulator said in a statement today. Novo, the world’s largest insulin maker, needs Tresiba, a long-acting insulin analogue, to wrest market share from Paris- based Sanofi (SAN)’s best-selling diabetes treatment, the Lantus insulin. Bagsvaerd, Denmark-based Novo’s older product, Levemir, has been trailing Lantus, which garnered 3.92 billion euros ($5.1 billion) in sales last year. “This new insulin is key for future growth,” Philippe Lanone and Beatrice Muzard, analysts at Natixis Securities in Paris, wrote in a Sept. 12 note. They estimate Tresiba may garner annual peak sales of 19.5 billion kroner ($3.4 billion) by 2025.

Read at BusinessWeek
Read at Reuters
Read at RTT News

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES